GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Debt-to-EBITDA

SNY (Sanofi) Debt-to-EBITDA : 2.60 (As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sanofi Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sanofi's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $10,242 Mil. Sanofi's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $15,324 Mil. Sanofi's annualized EBITDA for the quarter that ended in Jun. 2024 was $9,843 Mil. Sanofi's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 2.60.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sanofi's Debt-to-EBITDA or its related term are showing as below:

SNY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.25   Med: 1.63   Max: 2.68
Current: 2.2

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sanofi was 2.68. The lowest was 1.25. And the median was 1.63.

SNY's Debt-to-EBITDA is ranked worse than
57.77% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.78 vs SNY: 2.20

Sanofi Debt-to-EBITDA Historical Data

The historical data trend for Sanofi's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Debt-to-EBITDA Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.43 1.25 1.94 1.48 1.46

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.87 1.23 1.65 1.48 2.60

Competitive Comparison of Sanofi's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Sanofi's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sanofi's Debt-to-EBITDA falls into.



Sanofi Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sanofi's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2529.989 + 17559.433) / 13744.82
=1.46

Sanofi's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10242.196 + 15324.004) / 9842.842
=2.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


Sanofi  (NAS:SNY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Sanofi Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sanofi's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi Business Description

Address
46, avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.